A new study has found that a combination of two drugs could enhance the immune system to treat one of the most common types of cancer in the world, bowel cancer. Also known as colorectal cancer, despite its widespread presence, the treatment options for this condition are limited. What the study specifically found was that this procedure could shrink the tumours caused by this condition by around 60%.

What Are The Drugs Involved

The trial involved the use of two immunotherapy drugs, botancilimab and balstilumab. It is a monoclonal antibody that works to stimulate the body's immune system to attack cancer. The study is a rather significant find, as it’s the first time that a consistent and durable response to immunotherapy has been reported in patients with solid MSS mCRC tumours.

The study was divided into several phases for more than 6 months. In the US trial, around around 101 patients with microsatile stable metastatic colorectal (MSS-mCRC) tumours showed a decrease . Around 61% of the patients experienced tumour shrinkage or stabilization after combined treatment with votancilumab and balstilumab. When it comes to downsides, diarrhea and fatigue were found to be the most common side effects or side effects of this drug.

These results are interesting and open to exploration. To date, immunotherapy has not been effective in patients with CNS-mCRC tumors. This study demonstrates the potential of the combination of botenlimab and balstilimab in the treatment of CNS mCRC, providing new hope for people diagnosed with colon cancer.

What Could This Mean For Bowel Cancer Treatment In The Future

The study is currently in the final stages of clinical trials, and the US Food and Drug Administration (FDA) hopes to quickly gain approval for its use because of the importance of this area that affects many people. The efficiency shown demonstrates the potential of botansilimab to contribute to broad antitumor immunity.

All in all, the combination of botensilimab and balstilimab represents a promising new direction in the treatment of colorectal cancer. This breakthrough could improve conditions for many patients worldwide and lights a new hope in the fight against this common disease. The results of this study show the effectiveness of immunotherapy in this field and how its potential to transform cancer treatment can only grow in the years to come.

Industrial chicken farms may be fueling the spread of diarrhea-causing Campylobacter bacteria, according to a new study.

Researchers from the University of Oxford found that industrial poultry farming has driven more than a 100-fold increase in the spread of Campylobacter.

Published in the Proceedings of the National Academy of Sciences (PNAS), the study found that the expansion of commercial poultry production has enabled bacterial strains once largely confined to wild birds to mix extensively within farmed chicken populations.

"Industrial farming has created one of the largest animal habitats on the planet. Our findings provide new evidence that human-driven environmental change can increase the spread of infectious diseases," said Professor Sam Sheppard, senior author of the study from the University of Oxford.

"As chicken populations have grown, bacteria that were once largely confined to wild birds have gained far more opportunities to enter poultry flocks, spread and become established. Understanding these evolutionary consequences is essential if we are to reduce future risks from zoonotic disease and antimicrobial resistance," he added.

Poultry Farming Has Accelerated Bacterial Spread

Researchers analyzed nearly 2,800 Campylobacter genomes collected from chickens and wild birds across 30 countries, including the UK and the US, between 1979 and 2024.

The analysis showed that the rapid global expansion of chicken farming has created ideal conditions for the bacteria to spread, exchange genetic material, and acquire traits that improve survival in commercial poultry environments.

Since the 1960s, the global chicken population has increased sevenfold to around 31 billion birds, with chickens now accounting for about 70% of all bird biomass on Earth. While this growth has helped make animal protein more affordable, it has also created favorable conditions for bacterial adaptation and transmission, the researchers argued.

How Are the Bacteria Thriving?

The genomic analysis identified several genetic changes linked to adaptation in poultry, including genes associated with:

• Antimicrobial resistance
• Oxidative stress tolerance
• Metal acquisition
• Motility

According to the researchers, these traits may help Campylobacter survive and spread more efficiently in modern poultry production systems. The study also suggests that densely populated commercial chicken flocks may act as ecological "pathogen sponges," absorbing and amplifying bacterial strains from multiple sources.

Growing Concern Over Antimicrobial Resistance

The researchers warned that rising antimicrobial resistance (AMR)—when bacteria become resistant to drugs used to treat infections—is making Campylobacter infections increasingly difficult to treat.

They also cited an earlier University of Oxford study, which found that 80% of human Campylobacter infections in Oxfordshire were linked to poultry meat, with many of those infections resistant to antibiotics.

What Is Campylobacter?

Campylobacter is the world's leading bacterial cause of diarrhea. According to the World Health Organization (WHO), it is one of the four leading global causes of diarrheal disease. Nearly one in 10 people worldwide falls ill from foodborne diseases each year, resulting in the loss of an estimated 33 million healthy life years.

Although infections are usually mild, they can become severe or even fatal in very young children, older adults, and people with weakened immune systems.

Common Symptoms

• Diarrhea, which may be bloody
• Abdominal pain
• Fever
• Headache
• Nausea
• Vomiting

Symptoms typically last three to six days. Deaths are rare and generally occur in people with severe underlying health conditions or those at the extremes of age.

Campylobacter bacteria are destroyed by thorough cooking. The WHO recommends proper cooking, safe food handling, and good kitchen hygiene to reduce the risk of infection.

The US Centers for Disease Control and Prevention (CDC) has reported its ninth gastrointestinal (GI) illness outbreak linked to a cruise ship in 2026 after 13 people fell ill aboard the National Geographic Sea Bird.

The CDC is investigating the incident, and the cause of the outbreak has not yet been identified. The affected vessel is operated by Lindblad Expeditions.

The latest incident is also the ship's fourth gastrointestinal illness outbreak in less than two months, following one outbreak each in May and June and a second outbreak in July.

“Eight of the 57 guests sailing aboard National Geographic Sea Bird reported being ill during its July 15 voyage, along with five crew members,” the CDC said in a statement. Their predominant symptoms include diarrhea, vomiting, and abdominal cramps.

In response, Lindblad Expeditions said it has intensified cleaning and disinfection measures and isolated affected passengers and crew members to help limit the spread of illness.

The company has also canceled three scheduled passenger voyages departing on July 20, July 25, and July 30 to carry out enhanced sanitation procedures.

The cruise operator said the pause will allow it "to conduct enhanced sanitation protocols aligned with the highest industry standards and provide additional time to help prevent the risk of further cases."

"We are working directly with affected guests to provide refunds, support and alternative travel arrangements," Lindblad told USA TODAY in an emailed statement.

What Are Gastrointestinal Illnesses?

Gastrointestinal illnesses, also known as gastroenteritis, are the inflammation of the stomach and intestines that causes vomiting, diarrhea, cramps in the abdomen, and occasionally fever or muscle pain.

Commonly called the "stomach flu," it is not caused by the flu virus and has nothing to do with respiratory infections. Rather, it is usually caused by infection or chemical irritants to the gastrointestinal (GI) tract. There are two main types:

1. Infectious gastroenteritis – due to viruses, bacteria, parasites, or fungi.
2. Chemical gastroenteritis – due to ingestion of poisonous substances such as some drugs, alcohol, or polluted food/water.

How Does Gastroenteritis Spread?

The most prevalent reason for gastroenteritis is the intake of contaminated food or water. It is also spread by contact with infected people or surfaces they have contacted. Some typical situations include:

• Consumption of undercooked meat or seafood
• Inadequate washing of hands after using the toilet
• Drinking unbottled or unfiltered water during travel

Though most individuals recover quickly, individuals with compromised immune systems—such as young children, the elderly, or those with chronic diseases—are at a higher risk for developing complications like dehydration and extended illness.

Symptoms Of Gastroenteritis

Acute gastroenteritis usually presents with a combination of the following:

• Sudden onset of watery diarrhea (non-bloody)
• Nausea and vomiting
• Abdominal cramps or bloating
• Low-grade fever
• General fatigue or muscle aches

These symptoms typically occur within 1–3 days of contact with the infection and can last anywhere from 24 hours up to two weeks, depending upon the cause and the immune response of the patient.

Extreme age groups, especially very young infants and the elderly, are at higher risk due to dehydration from diarrheal illness. However, deaths remain rare when proper care is provided.

What You Can Do To Stop Its Spread

Because of how fast viruses spread, experts highly recommend preventive actions such as:

• Wash your hands frequently with soap and warm water, especially after using the toilet or before preparing food.
• Avoid visiting hospitals or care homes if experiencing symptoms.
• Stay home for at least 48 hours after symptoms subside to prevent spreading the virus.

Johnson & Johnson is about to end what can be described as one of the most controversial lawsuits in the pharmaceutical industry. The pharma giant has agreed to pay $5.5 billion to settle tens of thousands of cases alleging that its baby powder and other talc products can cause ovarian cancer.

The settlement covers around 76,000 lawsuits pending across U.S. federal and state courts. It will be final after it gets approved by 95% of eligible claimants. If finalized, a few payments are expected to begin in 2027, with additional payouts extending into 2028.

Johnson & Johnson To Settle Talc-Cancer Lawsuit

According to Reuters, the settlement covers 99.75% of the remaining ovarian cancer claims against Johnson & Johnson.

The company has previously resolved most lawsuits involving mesothelioma, another cancer linked to alleged asbestos in its talc products.

The agreement comes after years of courtroom battles, manipulative bankruptcy strategies, and mixed trial verdicts.

It also follows a recent ruling by a U.S. federal judge questioning whether plaintiffs' expert witnesses had provided the court with sufficient scientific evidence that links talc use directly to ovarian cancer, a development that strengthened J&J's legal position ahead of negotiations.

Also read: US Man Says ChatGPT's Medical Advice Nearly Killed Him: How Safe Is AI for Health Questions?

Johnson & Johnson Continues To Plead 'Not Guilty'

Despite agreeing to the massive settlement, Johnson & Johnson continues to deny that its talc products caused cancer.

Erik Haas, the pharma company's Vice President of Litigation, said the claims were "meritless" and that the company chose to settle to obtain closure after years of litigation.

The company has consistently maintained that its talc products are safe, asbestos-free, and that the settlement does not constitute admission of any wrongdoing.

The law firms representing thousands of women reportedly welcomed the agreement, describing it as a long-awaited resolution after nearly a decade of tedious litigation.

According to Reuters, attorneys representing the claimants said the settlement delivers meaningful compensation to affected women and their families after years of legal ambiguity.

Also read: Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Ads: Should GLP-1 Users Be Concerned?

J&J Talc-Cancer Lawsuit: About The Controversial Case

The lawsuits became one of the largest mass tort cases. The case combined complex scientific questions with allegations that the company knew of possible health risks but failed to warn the consumers and continued to sell the products.

The case dates back more than a decade, when women who had regularly used Johnson's Baby Powder for feminine hygiene began filing lawsuits alleging that it had increased their risk of ovarian cancer.

Another group of lawsuits alleged that certain talc products contained asbestos, a known carcinogen that could cause mesothelioma.

Johnson & Johnson has repeatedly denied that its talc products contain asbestos or caused cancer.

The first major jury verdict awarded $72 million to the family of Jacqueline Fox, who died from ovarian cancer after decades of talc use. Although the verdict was later overturned, it sparked thousands of similar lawsuits.

A California jury awarded $417 million to Eva Echeverria, who claimed long-term use of Baby Powder caused her ovarian cancer.

One of the largest verdicts came when 22 women were awarded $4.69 billion (later reduced on appeal to $2.1 billion) after a Missouri jury found J&J liable for failing to warn consumers about asbestos in their talc products.

Some studies found a link between genital talc use and ovarian cancer, whereas others found insufficient evidence. This disagreement remains the highlight of the courtroom battles even today with no definite discovery.